WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Iora Health
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Research
Exscientia, Bristol Myers Squibb | May 20, 2021
Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...
PHARMACY MARKET
PR Newswire | October 19, 2023
Halozyme Therapeutics, Inc. announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds. In the study, the biologic was delivered with Halozyme's proprietary high-volume auto-injector (HVAI) in healthy volunteers. The injecti...
Reuters: | February 19, 2020
Novartis AG (NOVN.S) and Bayer AG (BAYGn.DE) are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters. Other drugmakers set to raise prices at the start of 2019 include Allergan Plc (AGN.N), GlaxoSmithKline Plc (GSK.L), Amgen Inc (AMGN.O), AstraZeneca Plc (AZN.L) and Biogen Inc (BIIB.O), the doc...
Business Insights
Novavax, Inc. | August 16, 2022
Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that it submitted an application to the U.S. Food and Drug Administration for Emergency Use Authorization of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a homologous and heterologous booster in adults aged 18 a...
Article
Video
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE